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ABSTRACT
INTRODUCTION: The ageing population means prescribing for chronic illnesses in older people is 
expected to rise. Comorbidities and compromised organ function may complicate prescribing and in-
crease medication-related risks. Comorbid depression in older people is highly prevalent and complicates 
medication prescribing decisions. 
AIM: To determine the prevalence of potentially inappropriate medication use in a community-dwelling 
population of older adults with depressive symptoms.
METHODS: The medications of 191 community-dwelling older people selected because of depressive 
symptoms for a randomised trial were reviewed and assessed using the modified version of the Beers’ 
Criteria. The association between inappropriate medication use and various population characteristics 
was assessed using Chi-square statistics and logistic regression analyses.
RESULTS: The mean age was 81 (±4.3) years and 59% were women. The median number of medications 
used was 6 (range 1–21 medications). The most commonly prescribed potentially inappropriate medica-
tions were amitriptyline, dextropropoxyphene, quinine and benzodiazepines. Almost half (49%) of the 
participants were prescribed at least one potentially inappropriate medication; 29% were considered to 
suffer significant depressive symptoms (Geriatric Depression Scale ≥5) and no differences were found 
in the number of inappropriate medications used between those with and without significant depressive 
symptoms (Chi-square 0.005 p=0.54). 
DISCUSSION: Potentially inappropriate medication use, as per the modified Beers’ Criteria, is very 
common among community-dwelling older people with depressive symptoms. However, the utility of the 
Beers’ Criteria is lessened by lack of clinical correlation. Ongoing research to examine outcomes related to 
apparent inappropriate medication use is needed. 
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Introduction
It has been estimated that by 2030 the world 
population is likely to include 1 billion people 
over the age of 65 years, accounting for approxi-
mately 13% of the total world population.1 Due 
to the higher prevalence of diseases in older 
people, they are more likely than their younger 
counterparts to be prescribed medications. Some 
studies have shown that, on average, medication 
use increases by 52% after the age of 65 years.2 
Several studies have shown an increased risk for 
medication-related morbidity and mortality, with 
a higher number of medications prescribed.3–5 
Late-life depression is also common in older 
people, affecting between 17 and 30% of older 
community dwellers over the age of 65 years.6 As VOLUME 5 • NUMBER 3 • SEPTEMBER 2013  JOURNAL OF PRIMARY HEALTH CARE 183
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WHAT GAP THIS FILLS
What we already know: Older people use many medications and the use 
of inappropriate medication is higher in those with mental health needs. 
What this study adds: The study found that almost half of those recruit-
ed in a community sample of people with depressive symptoms were using 
inappropriate medications according to the Beers’ Criteria. Outcomes related 
to medication use are needed to fully understand the risk from inappropriate 
use as identified by use of the Beers’ Criteria. 
symptoms of depression in this population may 
be confounded by symptoms of comorbid chronic 
illnesses, or perceived as a natural progression 
of ageing, depression often goes undiagnosed.6 
Consequently, treatment of depression in this 
population, already complicated by ageing factors 
and medication-related issues, can be part of 
complex prescribing decisions. 
Furthermore, a number of studies have suggested 
that medications are not always used appropri-
ately in older people.7–12 Individuals aged 65 
years and older are more prone to adverse drug 
reactions than younger people.13 Inappropriate 
use of medication in older adults may include the 
overuse of drugs, prescribing medications that 
are predicted to be poorly tolerated by the elderly, 
prescribing medications that are highly likely to 
exacerbate a clinical condition (e.g. recurrent falls 
from over-sedation with benzodiazepines) and 
underutilisation of appropriate medications (e.g. 
low-dose aspirin).14,15 Those with depression are 
particularly at risk of adverse drug events, due 
to increased medications needed and increased 
comorbidity.16
Both explicit (e.g. Beers’ Criteria10) and implicit 
(e.g. Medication Appropriateness Index14) instru-
ments can be used to assess appropriate use of 
medications for older individuals in hospital and 
community settings. The biggest difference in 
application between the two instruments is that 
clinical expertise is required when using implicit 
criteria. The Medication Appropriateness Index, 
for example, measures prescribing appropriate-
ness according to 10 short questions covering 
the indication, effectiveness, dose, administra-
tion, drug–drug interactions and drug–disease 
interactions and cost. The Beers’ Criteria, on the 
other hand, defines inappropriate medications as 
those which should be avoided in older people, 
as the risks associated with their use outweigh 
their benefits.10,12 The Beers’ Criteria is divided 
into two lists which examine appropriateness 
of medication use in specific clinical conditions 
(condition-dependent list), and medications that 
are inappropriate regardless of the presence of a 
particular comorbidity (condition-independent 
list).4,14,17–20 The lists identify specific drugs or 
drug prescriptions (excessive dose, excessive treat-
ment duration, inappropriate drug combination 
and coexisting illness) with unfavourable benefit/
risk ratio or questionable efficacy.10,21–22 While 
the Beers’ Criteria have been used worldwide to 
evaluate inappropriate medication prescribing, 
there are no currently available reports on its 
clinical utility or validity to assist with im-
proving prescribing in elderly individuals with 
depression. In addition, geographic variation has 
been described,23 with no comparable data in 
New Zealand (NZ). 
In this paper, we report a community-based 
study assessing the potentially inappropriate use 
of medications according to the Beers’ Criteria 
among community-dwelling elderly subjects 
with symptoms of depression. The aims of this 
study are: 
a.  to describe the pattern of medication use in 
older people with depressive symptoms at 
enrolment; 
b. to assess medication inappropriateness in 
all enrolled participants using a modified 
version of the Beers’ Criteria to reflect the NZ 
context; and 
c.  to contrast the use of inappropriate medication 
in older individuals with and without 
significant depressive symptoms. 
Methods
Data sources and study population
The medications used by 193 elderly people en-
rolled in the Depression in Late Life Intervention 
Trial of Exercise (DeLLITE) study24,25 were used 
as our data source. The DeLLITE study enrolled 
people aged 75 years and over living in the com-
munity who agreed to participate in a trial of 184  VOLUME 5 • NUMBER 3 • SEPTEMBER 2013  JOURNAL OF PRIMARY HEALTH CARE
a physical activity programme to improve their 
symptoms of depression. The detailed sampling 
strategy of participants in the DeLLITE study is 
described elsewhere.24,25 In brief, general practi-
tioners invited all their patients aged 75+ to par-
ticipate using a letter and a three-question screen 
for depression26 to identify those with depressive 
symptoms. Those who were ‘screened’ as having 
depressive symptoms (two or more positive ques-
tions about depression), and who were interested, 
were visited at home to obtain written informed 
consent and to complete initial data collection. 
Data collection
Trained research nurses used standardised struc-
tured questionnaires to ascertain demographic, 
health and social information from the partici-
pants. Age and gender and comorbidities, includ-
ing cardiovascular disease, arthritis, history of 
syncope and/or falls, and a previous history of 
depression were determined during the interview. 
The severity of the depressive symptoms was 
established using the Geriatric Depression Scale 
(GDS), and was categorised according to standard 
criterion cut-off scores into ‘without significant 
depressive symptoms’ (score of 0 to 4) or ‘with 
significant depressive symptoms’ (score of 5 and 
above).27 Full clinical data regarding the severity 
of the medical conditions or prior treatments was 
not available. Research nurses viewed all medica-
tions at the participants’ home and recorded 
medication name, strength and frequency from 
the bottles/packs and/or blister packs. Over-the-
counter products and complementary supple-
ments used were also recorded. All medications 
were coded by therapeutic class, utilising the 
ATCC (Anatomical Therapeutic Chemical Clas-
sification) system developed by the World Health 
Organization (WHO) Collaborating Centre for 
Drug Statistics Methodology.28 
Assessment of appropriateness 
of medication
Both the condition-dependent and condition-
independent lists of the Beers’ Criteria—adapted 
to the current product availability in NZ—were 
used to assess the appropriateness of medications 
used in the population sampled. The use of medi-
cations in NZ is guided by the Pharmaceutical 
Management Agency (PHARMAC), a govern-
ment agency setting a formulary of publicly 
subsidised drugs. Access to the more expensive 
medications may be guided by an additional au-
thority, which involves applying to a central body 
using set criteria. Medications that were not reg-
istered for use in NZ (at the time of the review in 
2008) were omitted from both lists of the Beers’ 
Criteria (e.g. meprobamate and ticlopidine) but 
medications that were registered for use but not 
subsidised by PHARMAC were included (e.g. 
chlorpropamide). Details of the drugs included 
in the lists can be found in the appendices in 
the web version of this paper. In the condition-
dependent criteria, available medications that 
are used in NZ were incorporated into the list 
(shown in Appendix 1 in italics). 
As not all the health problems experienced by 
the study population were listed in the original 
Beers’ Criteria, the medical conditions in the 
condition-dependent list were expanded to ac-
commodate some of the medical comorbidities 
reported by the DeLLITE participants (Appen-
dix 2, medical conditions in italics).
Herbal and complementary medications were not 
assessed. All prescription items were assessed 
based on the adapted version of the Beers’ Crite-
ria (Appendices 1 and 2). 
Data analysis
Participant data was entered into IBM SPSS 
statistical package (version 19). Frequencies, such 
as the number of participants on potentially inap-
propriate medications (PIMs) according to age, 
gender and depression scores were calculated. The 
association between inappropriate medication use 
and depression scores was assessed using the Chi-
square statistic and logistic regression analysis to 
control for age, gender and comorbidities. 
Results
Participant characteristics
A total of 353 individuals were eligible for the 
DeLLITE study, of which 193 were enrolled as 
participants.25 Only those with complete medica-
tion data were eligible for inclusion in the present 
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study (n=191). Participants were predominantly 
women (59%) and had a mean age of 81 (stand-
ard deviation [SD] 4.3) years. The majority of 
medical conditions reported by the participants 
included cardiovascular disease (24%), arthritis 
(22%), history of syncope and/or falls (17%), and a 
previous history of depression (15%). Of the 191 
participants, 55 (29%) had a GDS score of five or 
higher (significant depressive symptoms) and 56% 
of these participants were female. The majority 
(62%) of the participants in this subgroup were 
over the age of 85 years.
A total of 1440 medications were used by the 
191 participants, of which 1329 were prescrip-
tion medications and 111 were over-the-counter 
products. Every participant was prescribed at 
least one medication with a median number of six 
and a range of 1–21 medications. Polypharmacy 
(defined as the simultaneous use of 10 or more 
regular prescription medications) was identified 
in 23% of the participants. Cardiovascular drugs 
were the most commonly prescribed, with 81% 
of participants taking at least one cardiovascular 
medication. Fifty-two per cent of the participants 
were prescribed at least one or more CNS (central 
nervous system) medications. 
Table 1 shows that overall there were no signifi-
cant differences in the participant characteristics 
amongst those who were versus those who were 
not using any PIMs. Ninety-three participants 
(49% of our study population) were prescribed at 
least one PIM and inappropriate use was associ-
ated with using a greater number of medications 
(mean 8.5 medications for those with at least 
one inappropriate medication used vs 5.7, t 5.5 
p<0.001). 
Potentially inappropriate medications
Almost half (49%) of the participants were 
prescribed at least one potentially inappropriate 
medication. As presented in Table 2, a total of 
134 PIMs were identified using the modified 
Beers’ Criteria (either condition-dependent or 
condition-independent), of which 53 (40%) were 
CNS medications, namely amitriptyline (23%), 
dextropropoxyphene (17%), fluoxetine (11%), 
dothiepin (11%) and diazepam (7%). The most 
commonly prescribed potentially inappropriate 
medications were amitriptyline, dextropropoxy-
phene, quinine and benzodiazepines. The major-
ity of amitriptyline prescribed was low-dose (i.e. 
10 mg daily). Of the benzodiazepines, 55% were 
prescribed above the recommended dose range 
suggested by the Beers’ Criteria. The second 
most commonly prescribed PIMs were those act-
ing on the musculo  skeletal system (16%), namely 
quinine (57%), naproxen (24%) and diclofenac 
(>100 mg daily; 9.5%). There were more partici-
pants on inappropriate medications according to 
the condition-independent list than according 
to the condition-dependent list of the Beers’ 
Criteria (36% versus 26%; see Table 3). 
The proportion of participants taking at least one 
PIM according to the condition-independent list 
was 35% (n=70), with 76% (n=56) of these medica-
tions considered high severity. The proportion of 
participants on inappropriate medication accord-
ing to the condition-dependent list was 26%. 
Table 1. Use of inappropriate medication according to the Beers’ Criteria in older community-dwelling people with 
depressive symptoms
No inappropriate use 
(n=98)
At least one inappropriate use 
(n=93)
Total 
(N=191)
Age: mean (SD) 81.2 (4.3) 81.0 (4.5) 81.1 (4.3)
Female: n (%) 57 (58) 56 (60) 113 (59)
GDS score: n (%) 0–4 70 (71) 66 (71) 136 (71)
≥5 28 (29) 27 (29) 55 (29)
Total medications  5.7 (3.0) 8.5 (3.8)* 7.0 (3.6)
GDS  Geriatric Depression Scale
*  t 5.5 p<0.001
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Table 2. Therapeutic medication use and inappropriate medication use in subgroups with and without significant depressive symptoms as assessed by 
the Geriatric Depression Scale (N=191 participants)
Therapeutic classes of medications outlined in Beers’ Criteria 
(n=1329)
Any use 
(n=273)
Frequency of inappropriate use of medication 
Total 
(n=134)
Subgroup with 
GDS ≥5 (n=44)
Subgroup with 
GDS <5 (n=90)
Cardiovascular (n=414 ) 20 7 13
Doxazosin 5 5 3 2
Amiodarone 4 4 0 4
Digoxin (≥ 0.125 mg) 9 4 2 2
Metoprolol* 46 3 0 3
Nifedipine 5 3 2 1
Atenolol* 15 1 0 1
Musculoskeletal (n=105) 21 7 14
Quinine* 14 12 4 8
Naproxen 5 5 2 3
Diclofenac (≥100 mg)† 8 2 1 1
Alendronate* 23 1 0 1
Sulindac 1 1 0 1
Central nervous system (n=226) 53 15 38
Central nervous system (excluding paracetamol) (n=164) 53 15 38
Amitriptyline† 12 12 1 11
Dextropropoxyphene (with paracetamol preparation) 9 9 4 5
Fluoxetine, daily 6 6 3 3
Dothiepin† 6 6 0 6
Diazepam † 4 4 1 3
Triazolam ≥ 0.250 mg) 12 4 2 2
Oxazepam* 8 4 0 4
Temazepam† 5 2 1 1
Nortriptyline* 6 1 0 1
Lorazepam* 4 1 1 0
Clonazepam* 2 1 1 0
Valporic acid * 2 1 0 1
Phenobarbitone (not indicated for epilepsy) 1 1 1 0
Doxepin† 1 1 0 1
Anti-infective (n=1) 1 0 1
Nitrofurantoin 1 1 0 1
Alimentary tract and metabolism (n=275) 16 6 10
Docusate/senna, regularly 17 8 3 5
Antacid* 6 6 2 4
Dicycloverine 1 1 0 1
Bisacodyl 1 1 1 0
Blood and blood forming (n=150) 16 5 11
Dipyridamole 9 9 3 6
Aspirin 300 mg* 18 7 2 5
Respiratory (n=74) 2 1 1
Promethazine 2 2 1 1
Genitourinary (n=18) 5 3 2
Oxybutynin 5 5 3 2
Anti-neoplastic and immunomodulating (n=4) 0 0 0
Dermatological (n=13) 0 0 0
Sensory (n=23) 0 0 0
Systemic—hormonal (n=13) 0 0 0
Various—nutrition (n=2) 0 0 0
GDS  Geriatric Depression Scale
*  Medications sourced solely from condition-dependent list
†  Medications sourced from both condition-independent and condition-dependent lists
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When inappropriate use was compared between 
those with significant depressive symptoms (GDS 
≥5) and those without (GDS <5), there were no 
significant differences observed (27 of 55 par-
ticipants [49%] in the subgroup with significant 
depressive symptoms compared with 66 of 136 
participants [49%] in the subgroup without sig-
nificant depressive symptoms [Chi-square 0.005, 
p=0.54]. The association between inappropriate 
medication use, controlling for age, gender and 
other comorbidities, and significant depressive 
symptoms was also assessed using logistic regres-
sion analysis. Again, no significant correlates 
were found.
Discussion
The results of our study showed a high preva-
lence (49%) of inappropriate medication use in a 
sample of older people in primary care selected 
for a study because of depressive symptoms. 
When enrolled in the study and assessed, the 
subgroup with significant depressive symptoms 
(those with a GDS score >5), had no more inap-
propriate medication use than those with a GDS 
score <5. The mean number of medications per 
participant was 7 (SD 3.6), with those using PIMs 
taking more medications (8.5 vs 5.7). Slightly 
lower rates of inappropriate use have been found 
in other studies, with reported incidences be-
tween 14 and 32% of older participants in home 
care facilities and nursing homes taking at least 
one inappropriate medication.11,20,29–31 A study by 
Baker et al.32 examining inappropriate medication 
use in older adults with mental illness using the 
modified version of Beers’ Criteria 2003 found 
that of 153 older adults (mean age 76 years old, 
range 52–95 years), 30.7% (47/253) were receiv-
ing at least one inappropriate medication. Only 
the condition-independent list had been applied 
in Baker’s audit. The most commonly prescribed 
inappropriate medications were diazepam, fer-
rous sulfate, temazepam and lorazepam. Despite 
similar population demographics, Baker et al. had 
omitted the utilisation of the condition-depend-
ent list completely in determining appropriate 
medication use. The partial utilisation of Beers’ 
Criteria may underestimate the level of inappro-
priate prescribing in an older population where 
multiple comorbidities often coexist. Although 
not conclusive due to the limited number of com-
parable studies, the full utilisation of Beers’ Cri-
teria (both condition-independent and condition-
dependent lists) could have contributed to the 
higher rate observed in our study population. The 
DeLLITE sample was chosen as a source of study 
participants because many people in that sample 
had shown depressive symptoms and many of the 
Table 3. Inappropriate use of medication according to the Beers’ Criteria in those with and without depressive symptoms
a. Condition–dependent list
Inappropriate use 
of medications
Participants n (%)
Depressive status n (%)
GDS ≥5 (n=55) GDS <5 (n=136)
One 41 (21) 10 (18) 31 (23)
Two 4 (2.1) 1 (1.8) 3 (2.2)
Three 2 (1.0) – 2 (1.5)
Four 3 (1.6) 1(1.8) 2 (1.5)
Total 50 (25.7) 12 (21.6) 38 (28.2)
b. Condition–independent list
Inappropriate use 
of medications
Participants n (%)
Depressive status n (%)
GDS ≥5 (n=55) GDS <5 (n=136)
One 54 (28) 16 (29) 38 (28)
Two 14 (7.2) 5 (9) 9 (6.6)
Three 2 (1.0) 2 (3.6) –
Total 70 (36) 23 (42) 47 (35)
GDS  Geriatric Depression Scale
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antidepressants in use were deemed inappropriate 
according to the Beers’ Criteria. The inappropri-
ate medications with the most frequent occur-
rence found were amitriptyline (23%), fluoxetine 
(11%), and dothiepin (11%). 
Age is one of the most influential factors in 
determining appropriate prescribing; however, 
age was not related to inappropriate use in this 
sample (not significant in the regression analysis). 
The study participants were 75 years or over, 
older than those in other studies10,15,19 and inter-
individual variability in health, disease and dis-
ability increases substantially with age. Further-
more, various health care settings studied and the 
use of different versions of the Beers’ Criteria in 
other studies may be factors in contributing to 
the higher prevalence of inappropriate medication 
use observed in our population. Lastly, one of 
our hypotheses for the high level of inappropri-
ate prescribing in this group of individuals may 
be because our study sample all had depressive 
symptoms at enrolment and depression is recog-
nised as being related to increased medication 
use.23 Our study did not show that those with 
significant depressive symptoms (i.e. GDS ≥5) 
were using potentially inappropriate medications 
significantly differently from those with GDS 
scores within the normal range. However, the 
sample studied had a high prevalence of depres-
sive symptoms by design, and thus would be 
expected to be different than a general population 
sample of older people. 
The Beers’ Criteria are limited in assessing 
medication appropriateness. As purely ex-
plicit criteria, they do not allow for clinical 
judgment. For example, the majority of the 
amitriptyline doses reported in our study 
population are considered low for an antide-
pressant indication (i.e. 10 mg nocte), but may 
be adequate for neuropathic pain or urinary 
incontinence. Low dose tricyclic antidepres-
sants (TCA), such as amitriptyline, may be 
the first-line choice for managing neuropathic 
pain. However, the Beers’ Criteria consider any 
use of amitriptyline as inappropriate, even if 
used at lower doses. Other examples include 
amiodarone and doxazosin. Both were common-
ly prescribed in our sample population and in 
some situations are the only effective medica-
tions. Furthermore, Beers’ Criteria has strict, 
and to some extent inflexible, criteria that label 
certain medication use as inappropriate even in 
situations where it may be the only effective 
treatment. Anxiety is one of the most difficult 
clinical mental health conditions to manage and 
is often non-responsive to single antidepressant 
management, requiring the initial use of benzo-
diazepines to effectively control the associated 
symptoms while awaiting a response to the 
antidepressant. The rate of inappropriate use of 
medications in this study may be, therefore, 
over-estimated and other studies are needed 
linking Beers’ Criteria recommendations to 
outcomes from medications to further assess 
the suitability and generalisability of the Beers’ 
Criteria in the mental health population.
In 2012, a new version of the Beers’ Criteria was 
developed in collaboration with the American 
Geriatrics Society. Although the Beers’ Criteria 
2012 was not used in our study, it is interesting 
to find that this new version has addressed sev-
eral of the limitations we found with the older 
version. 
The new version has removed medications that 
are no longer available and added in drugs in-
troduced since 2003. Notable new inclusions are 
thiazolidinediones or glitazones for those with 
heart failure, acetylcholinesterase inhibitors for 
those with a history of syncope, and selective 
serotonin reuptake inhibitors in the context of 
patient falls and fractures. The new criteria have 
included ratings of the quality of the evidence 
supporting the panel’s recommendations. This 
may allow a more evidence-based application of 
the criteria. 
It has been consistently reported that the Beers’ 
Criteria should not substitute clinical judgment 
or the individualised decision-making process 
that must take place in consultation with patients 
and their caregivers. The criteria should primar-
ily be used to guide interventions and identify 
individuals for comprehensive medication review, 
rather than merely as identifying specific targets 
for discontinuation. 
In selecting the most suitable medication for 
this age group, clinical knowledge should guide 
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application of evidence-based knowledge. While 
use of Beers’ Criteria may not aid prescrib-
ing decisions, it has the potential to ‘red-flag’ 
problematic drugs using its explicit criteria to 
signal involvement of the multidisciplinary team 
(i.e. specialists and pharmacists) to assist with 
the prescribing process in complex populations. 
In general, the following points remain sensible 
advice on prescribing for older people: 
•	 avoid medication with high anticholinergic 
side effects; 
•	 start with the lowest dose with titration to 
effect; 
•	 aim for disease modification rather than 
treating symptoms; and 
•	 avoid short-acting sedative hypnotics. 
Managing mental health problems appropriately 
may mean use of medications on the Beers’ Crite-
ria list is necessary. 
Study limitations
This research was conducted in a relatively small 
sample and thus generalisability to a large sample 
is unlikely. All study participants were recruited 
from general practices in central Auckland and 
were selected specifically as they scored 2 or 
more on the three-question depression screening 
tool, which means results may be more perti-
nent to those with some depressive symptoms. 
This group with depressive symptoms would be 
expected to have a different medication profile 
than a general community sample. Secondly, the 
use of the Beers’ Criteria 2003 is based on con-
sensus only. The use of the most updated Beers’ 
Criteria 2012, which is both consensus based and 
evidence based, may result in more confidence in 
applying explicit criteria and instituting risk miti-
gation to avoid potentially inappropriate medica-
tion use. Finally, the comorbidities identified in 
study participants were not always available as 
specifically listed conditions in the Beers’ Criteria 
condition-dependent list. For example, asthma/
COPD is the condition listed in the condition-
dependent list, whereas the patient’s diagnosis 
was bronchiectasis. Better clinical correlation is 
needed when using any medication quality as-
sessment process and this study is limited by not 
having access to adequate clinical information.
Conclusion 
Almost half of our study population were receiv-
ing at least one inappropriate medication as per 
the modified Beers’ Criteria used in this study, 
and clinical correlation was needed to truly 
decide if medication was inappropriate. No differ-
ences were observed in inappropriate medication 
use between those with and without significant 
depressive symptoms according to GDS score. 
Ongoing research to examine outcomes related to 
this medication use is needed. In the meantime, 
increased awareness of prescribing options is 
recommended. 
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ORIGINAL SCIENTIFIC PAPERS
APPENDIX 1: Adapted Beers’ Criteria:  
Condition-independent list 
Drug Class Drug names/doses if specified Severity Comments
Long-acting benzodiazepines 
(BZD)
•	 Diazepam High These agents have very long half-lives, cause prolonged 
sedation and increase the risk of falls and fractures.
If BZD therapy is unavoidable, use short-acting agents.
Short-acting BZDs, should 
rarely exceed the dose listed
•	 Lorazepam (3 mg)
•	 Oxazepam (60 mg)
•	 Triazolam (0.25 mg)
•	 Temazepam (15 mg)
High With rare exceptions, the agents should be used only in 
persons who are physically dependent or who are being 
treated with short-course therapy for an acute condition.
Barbiturates except 
phenobarbital for seizures
High All use should be avoided except in individuals who are 
physically dependent or for seizure disorder management.
There are safer sedative-hypnotics available.
•	 Amitriptyline
•	 Doxepin
High Amitriptyline and doxepin are very sedating and 
anticholinergic—their use should be avoided.
•	 Methyldopa
•	 Methyldopa-hydrochlorothiazide
High All use should be avoided. Methyldopa causes bradycardia 
and can exacerbate depression in the elderly. Safer 
antihypertensives are available.
•	 Propoxyphene (Paradex®) Low All use should be avoided; it has little advantage over 
acetaminophen. Other analgesics are safer and more effective.
•	 Diphenhydramine (Unisom®) High Use only in the smallest effective dose (50 mg daily at night 
maximum, no more than 7 days) and only for emergency 
treatment of allergic reactions. Causes confusion and sedation.
Anticholinergics and 
antihistamines
•	 Chlorpheniramine (Histafen®)
•	 Diphenhydramine (Unisom®)
•	 Hydroxyzine (Serecid®)
•	 Promethazine (Phenergan®, 
Allersooth®)
•	 Dexchlorpheniramine 
(Polaramine®)
High All non-prescription and many prescription antihistamines can 
have potent anticholinergic effects and cause confusion and 
sedation. To treat allergic reactions, use non-anticholinergic 
antihistamines rather than these agents.
•	 Dipyridamole Low Short-acting form may cause orthostatic hypotension. Long-
acting form may be appropriate in persons who have artificial 
heart valves.
Dipyridamole SR is considered appropriate while dipyridamole 
short-acting is not.
•	 Digoxin Low Doses should not exceed 0.125 mg/day except when treating 
artificial arrhythmias. Diminished renal clearance increases risk 
for toxicity.
•	 Ferrous sulphate >325 mg/day High Higher doses do not substantially increase iron absorption but 
do cause increased constipation.
Muscle relaxant
anti-spasmodics
•	 Oxybutynin High The doses needed to achieve a therapeutic effect generally 
produce anticholinergic side effects poorly tolerated by the 
elderly.
Non-COX selective NSAID
(long-term use of full doses)
•	 Naproxen
•	 Ketorolac
•	 Indomethacin 
High Potential for renal failure, gastrointestinal bleeding, 
hypertension and heart failure.
•	 Daily fluoxetine High Has a long half-life and can produce insomnia and agitation. 
Safer alternatives exist.
Long-term use of stimulant 
laxative
•	 Bisacodyl (Ducolax®) High May be appropriate in the presence of opiate analgesic use. 
Otherwise, may exacerbate bowel dysfunction.A2—WEB VERSION ONLY  VOLUME 5 • NUMBER 3 • SEPTEMBER 2013  JOURNAL OF PRIMARY HEALTH CARE
QUANTITATIVE RESEARCH: APPENDIX 1
ORIGINAL SCIENTIFIC PAPERS
Drug Class Drug names/doses if specified Severity Comments
•	 Amiodarone High Associated with QT prolongation and torsades de pointes. 
Lack of efficacy in the elderly.
•	 Nitrofurantoin High Potential for renal impairment; safer alternatives exist.
•	 Doxazosin Low Potential for hypotension and dry mouth. Can exacerbate 
symptoms of stress incontinence and mixed-cause 
incontinence.
•	 Short-acting nifedipine  
(Adalat 10®, Adalat 20®, Nyefax 
Retard®)
High Potential for hypotension and constipation.
Short-acting nifedipine means long-acting (as it is being 
compared with the extended release formulation).
Oral oestrogens •	 Conjugated oestrogen 
(Premarin®)
Low Carcinogenic effects (breast and endometrial cancer).
Gastrointestinal 
antispasmodics
•	 Dicyclomine (Merbentyl®)
•	 Propantheline 
High All have uncertain effectiveness and are strongly 
anticholinergic. Avoid all use—particularly long-term use.
•	 Disopyramide High Of all antiarrhythmic drugs, this is the most potent inotrope 
and therefore may induce heart failure in elderly patients. It 
is also strongly anticholinergic. Other antiarrhythmic drugs 
should be used. 
•	 Chlorpropamide  High  It has a prolonged half-life in elderly patients and could 
cause prolonged hypoglycaemia. Additionally, it is the only 
oral hypoglycaemic agent that causes SIADH (Syndrome of 
Inappropriate Antidiuretic Hormone). 
•	 Orphenadrine  High  Causes more sedation and anticholinergic adverse effects than 
safer alternatives.
•	 Cimetidine Low CNS (central nervous system) adverse effects including 
confusion.
•	 Clonidine  Low Potential for orthostatic hypotension and CNS adverse effects.
Medications not included as not registered and unavailable in New Zealand
Independent of diagnosis 
1. Pentazocine
2. Trimethobenzamide
3. Methocarbamol
4. Carisoprodol
5. Chlorzoxazone
6. Cyclobenzaprine
7. Metazalone
8. Chlordiazepoxide-amitriptyline
9. Perphenazine-amitriptyline
10. Meprobamate 
11. Chlordiazepoxide 
12. Clidinium-chlordiazepoxide
13. Halazepam 
14. Chlorazepate
15. Reserpine 
16. Dicyclomine 
17. Cyproheptadine
18. Tripelennamine
19. Cyclandelate
20. Meperidine
21.. Ticlopidine
22. Oxaprozin
23. Ethacrynic acid 
24. Guanethidine
25. Isoxsuprine
26. Thioridazine
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APPENDIX 2. Adapted Beers’ Criteria: 
Condition-dependent list*
Medication Disease or condition Comments Severity
High sodium content drugs
(sodium and sodium salts [alginate bicarbonate, 
bisphosphate, citrate, phosphate, salicylate and 
sulphate])
•	 Docusate	sodium
•	 Etidronate	disodium
•	 Phenytoin	sodium
•	 Aspro-Aspirin®	(300	mg)
•	 Quinine	sulphate
•	 Sodium	valproate
•	 Movicol®
•	 Gaviscon®
•	 Diclofenac	sodium
•	 Alendronate	sodium
Heart failure
Hypertension
Heart	attack/	angina
Enlarged	ventricle
Aortic	sclerosis
Negative inotropic effect. 
Potential to promote fluid 
retention and exacerbate 
heart failure. 
High
Aspirin >325 mg/day
Non-selective NSAIDs
•	 Ibuprofen
•	 Tenoxicam
•	 Diclofenac
•	 Naproxen
•	 Indomethacin
•	 Ketorolac
•	 Meloxicam
Gastric or duodenal ulcers
Gastric	reflux
May exacerbate existing 
ulcer disease or create new 
ulcers.
High
Clozapine
Chlorpromazine
Pericyazine
Bupropion
Seizure control
Epilepsy
These agents can lower the 
seizure threshold.
High
Aspirin
NSAIDs
•	 Ibupofen
•	 Ketorolac
•	 Indomethacin
•	 Tenoxicam
•	 Diclofenac
•	 Naproxen
•	 Meloxicam
•	 Coxibs
Dipyridamole
Clopidogrel
Disorders of blood clotting (including 
anticoagulant therapy)
•	 Warfarin
•	 Heparin
Increased risk of bleeding 
through multiple 
mechanisms of action. 
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Medication Disease or condition Comments Severity
Anticholinergics and antihistamines
•	 Chlorpheniramine
•	 Diphenhydramine
•	 Hydroxyzine
•	 Promethazine
•	 Dexchlorpheniramine
Gastrointestinal antispasmodics
•	 Dicyclomine
Muscle relaxants
Oxybutynin
Antidepressants
•	 Amitriptyline
•	 Imipramine
•	 Clomipramine
•	 Fluoxetine
•	 Citalopram
•	 Paroxetine
•	 Doxepin
•	 Dothiepin
•	 Nortriptyline
Decongestant (nasal sprays)
Tolterodine
Bladder flow obstruction
Prostate	problem
Prostatectomy
Can lead to urinary 
retention.
High
Alpha-blocker
•	 Doxazosin
•	 Terazosin
•	 Prazosin
Tricyclic antidepressants (TCA)
•	 Imipramine
•	 Doxepin
•	 Amitriptyline
•	 Dothiepin
•	 Clomipramine
Long-acting BZD
•	 Diazepam
Stress incontinence May worsen symptoms of 
incontinence.
High
TCA
•	 Imipramine
•	 Doxepin
•	 Amitriptyline
•	 Dothiepin
Arrhythmias
Atrial	fibrillation
Pacemaker
Proarrhythmic potential. High
Decongestant (nasal spray)
Theophylline
Methylphenidate
Monoamine oxidase inhibitors (MAOIs)
Insomnia CNS stimulant effects. High
Metoclopramide
Conventional antipsychotics
•	 Prochlorperazine
•	 Pericyazine
•	 Haloperidol
Barbiturates
•	 Phenobarbitone
Anticholinergics
Oxybutynin
Parkinson’s disease Antidopaminergic and 
anticholinergic effects 
can worsen symptoms of 
parkinsonism.
High
Barbiturates
Anticholinergics
Antispasmodics
Muscle relaxants
CNS stimulants
•	 Methylphenidate
Cognitive impairment
Neurological	problems
Dementia	(Alzheimer’s)
CNS-altering effects 
can worsen cognitive 
performance.
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Medication Disease or condition Comments Severity
Long-acting BZD
•	 Diazepam
Sympatholytic agents
•	 Methyldopa
Depression May produce or exacerbate 
depression.
High
Methylphenidate
Fluoxetine
Anorexia and malnutrition These agents suppress 
appetite.
High
Short to intermediate BZD
•	 Temazepam
•	 Oxazepam
•	 Triazolam
•	 Clonazepam
•	 Nitrazepam
•	 Lortazepam
•	 Lorazepam
TCA
•	 Imipramine
•	 Doxepin
•	 Amitriptyline
•	 Dothiepin
•	 Clomipramine
Syncope or fall
Hip	Fracture/Broken	bones
Osteoporosis
Collapse
Vertigo
Fainting	attacks
May produce ataxia, impair 
psychomotor function and 
increase falls.
High
SSRIs (selective serotonin reuptake inhibitors)
•	 Fluoxetine
•	 Citalopram
•	 Paroxetine
•	 Setraline
SIADH/Hyponatraemia May exacerbate or cause 
SIADH
Low
Olanzapine Obesity May stimulate appetite and 
cause weight gain.
Low
Diazepam
Beta-blockers
•	 Metoprolol
•	 Celiprolol
•	 Atenolol
•	 Propranolol
•	 Nadolol
Chronic Obstructive Pulmonary 
Disease (COPD)
Asthma	
Emphysema
Bronchiectasis
CNS adverse effects. 
May induce respiratory 
depression. May exacerbate 
or cause respiratory 
depression.
High
Calcium channel blockers
•	 Amlodipine
•	 Felodipine
•	 Nifedipine
•	 Verapamil
•	 Diltiazem
TCAs
•	 Imipramine
•	 Doxepin
•	 Amitriptyline
•	 Dothiepin
•	 Clomipramine
Anticholinergics
Chronic constipation May exacerbate 
constipation.
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Medications not included as not registered and unavailable in New Zealand
Considering Diagnosis 
1. Phenylpropanolamine
2. Thioridazine
3. Thiothixene
4. Ticlopidine
5. Flovoxate
6. Tacrine
7. Pemolin
8. Detroamphetamine
9. Methamphetamine
10. Reserpine
11. Guanethidine
12. Fluvoxamine
*  Italicised medical conditions are additions to include some of the medical comorbidities reported by DeLLITE study 
participants. Italicised drug names are additional medications that are used in New Zealand.